Navigation Links
Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)

CHAPEL HILL, N.C., Oct. 20 /PRNewswire/ -- With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, pharmaceutical, biotechnology and medical device industry executives are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes. In the recently published report by benchmarking firm, Best Practices, LLC, reviewing the CME support functions, benchmark respondents found significant opportunity for maximizing resources through centralization and innovative use of E-CME. Data from this study, "Educating the Market: Creating Value through Support of Continuing Medical Education," identified several key practices and metrics that can enable organizations to identify performance gaps and areas for improvement to better manage their CME support functions.

To view the study abstract or complimentary summary of the full report "Educating the Market: Creating Value through Support of Continuing Medical Education," click on the following link .

In a benchmarking study that included such influential companies as AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson & Johnson, Merck, Pfizer, Roche, Sanofi-Aventis and Wyeth, many key questions were covered, including:

-- What is the current landscape of continuing medical education (CME) in

North America and Europe?

-- What structural forms are used to deploy CME, optimize budgets & best

deliver content?

-- How rapidly is E-CME advancing?

-- What CME delivery channels are preferred?

-- What are the current trends and future directions of CME?

Among the key topics gathered in this report are:

-- Geographic delivery of CME

-- Structural management of CME

-- CME investment budgets for North America

-- CME investment budgets for Europe

-- CME investment staffing for North America

-- CME investment staffing for Europe

-- Mix of planned versus spontaneous CME investment

-- Functional responsibility for CME

-- Mix of CME delivery in North America (company directed versus 3rd

party, etc.)

-- Mix of CME delivery in Europe

-- Background & experience of CME employees

-- Tenure of CME employees

-- Mix of CME delivery modes for North America

-- Mix of CME delivery modes for Europe

-- Use of E-CME in North America & Europe

-- Effectiveness ratings for CME delivery activities in North America

-- Effectiveness ratings for CME delivery activities in Europe

For more information on this report, contact Robert Naylor at or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to .


Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
2. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
3. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
4. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
5. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
6. Best Practice Database Supports Bio-Pharma Product Launch
7. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
8. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
9. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
10. Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
11. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , ... Annual Healthcare Conference in New York City ... (1:30 p.m. GMT). --> SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> Shire ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):